1. Kappos L. Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler. 2004;10(suppl)S46-S55. [PubMed]

2. Bakshi R, Neema M, Healy BC, et al. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008;65:1449-1453. [PubMed]

3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452. [PubMed]

4. Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler. 2002;8:359-365. [PubMed]

5. Koch M, Uyttenboogaart M, van Harten A, De Keyser J. Factors associated with the risk of secondary progression in multiple sclerosis. Mult Scler. 2008;14:799-803. [PubMed]

6. Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci. 2007;255:35-41. [PubMed]

7. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med. 2002;53: 285-301. [PubMed]

8. Casanova B, Coret F, Valero C, et al. High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study. Mult Scler. 2002;8:59-63. [PubMed]

9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911. [PubMed]

10. Mostert JP, de Groot JC, Ramsaransing GS, Koch MW, De Keyser J. Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. Eur J Neurol. 2007;14:1210-1215. [PubMed]

11. Pulizzi A, Rovaris M, Judica E, et al. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. Arch Neurol. 2007;64:1163-1168. [PubMed]

12. Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage. 2008;42:315-322. [PubMed]

13. Ge Y, Grossman RI, Udupa LK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology. 2000;214:665-670. [PubMed]

14. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679-687. [PubMed]

15. European Study Group on Interferon in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on Interferon in Secondary Progressive MS. Lancet. 1998;352:1491-1497. [PubMed]

16. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial of IFN in secondary-progressive MS. Neurology. 2001;57:1969-1975. [PubMed]

17. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology. 2001;56:1496-1504. [PubMed]

18. Hommes OR, Maas-Enriquez M. ESIMS—an ongoing clinical trial in secondary progressive multiple sclerosis. Mult Scler. 2000;6(suppl 2):S27-S32. [PubMed]

19. Hartung HP, Gonsette R, Konig NM, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet. 2002;360:2018-2025. [PubMed]

20. Novantrone^® (mitoxantrone for injection concentrate) prescribing information. Rockland, MA: EMD Serono, Inc; 2009.

21. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology. 1998;51:239-245. [PubMed]

22. Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci. 2004;218:73-77. [PubMed]

23. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54:1145-1155. [PubMed]

24. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology. 1999;53:751-757. [PubMed]

25. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46:296-304. [PubMed]

26. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98-108. [PubMed]

27. Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation Autoimmune Diseases Working Party Database. Mult Scler. 2006;12:814-823. [PubMed]

28. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231. [PubMed]

29. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840-846. [PubMed]

30. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6:903-912. [PubMed]

31. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997;120:1085-1096. [PubMed]

32. Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 1990;300:631-634. [PubMed]

33. Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology. 2009;72:1330-1336. [PubMed]

34. Bieniek M, Altmann DR, Davies GR, et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:1036-1039. [PubMed]

35. Stevenson VL, Miller DH, Rovaris M, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology. 1999;52:839-845. [PubMed]

36. Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14-24. [PubMed]

37. Wolinsky JS, Shochat T, Weiss S, Ladkani D, for the PROMiSe Trial Study Group. Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. J Neurol Sci. 2009; May 7. Epub ahead of print. [PubMed]

38. Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev. 2009;21:CD006643. [PubMed]

39. Montalban X. Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. Mult Scler. 2004;10(suppl 1):S62-S64. [PubMed]

40. Hawker K, O’Connor P, Freedman M, et al. Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology. 2009; 72 (suppl 3): A254. Presented at the 61st Annual Meeting of the American Academy of Neurology, Seattle, Washington, April 25-May 2, 2009.